Item 8.01

Other Events
INVO Bioscience’s 2016 Annual Report on Form 10-K is not currently anticipated to be filed by the extended deadline of April 17, 2017 as intended. This is the result of a number of unexpected and time consuming events that we reported which occurred during the extension period. With our limited resources, we now do not expect to be able to complete all of the necessary work in a timely manner. However, we expect to be able to file the 2016 Form 10-K by April 24, 2017.
In addition, we would like to point out that, even if we file our 2016 Form 10-K by April 24, 2017, that late filing will not make the Company current in its reporting requirements. We have not filed our Form 10-Qs for the quarters ended March 31, 2016, June 30, 2016 or September 30, 2016. We expect to file those missing Form 10-Qs by May 15, 2017.
We would also like to respond to an item referenced in the letter from Claude Ranoux’s attorney (Jonathan A. Roberts, Esq.) dated April 11, 2017, which was filed as an exhibit with the Company’s 8-K/A filing yesterday, April 13, 2017. That letter states:
“With respect to any property in his possession, Dr. Ranoux will return any property belonging to INVO Bioscience to the Company. However, with respect to property originally owned by Medelle, we would ask you provide the basis, and any relevant documentation, regarding your assertion that this material belongs to the Company.”
This is referring to our request for Claude Ranoux to return any Company owned items in his possession, such as files, products, samples and equipment. As Dr. Ranoux is no longer an officer or director of INVO, we requested him to return those items as they are assets of INVO Bioscience.
INVO Bioscience, through its wholly owned subsidiary BioXcell, owns all of Medelle’s former assets, including patents. Dr. Ranoux purchased the assets of Medelle, and then transferred all of these assets to the Company when it was formed in 2007, as has been referenced in various Form10-K annual reports signed by Dr. Ranoux.


INVO Bioscience, Inc. is a medical device company. The Company is focused on creating various treatments for patients diagnosed with infertility. The Company’s product, the INVOcell, is a medical device used in infertility treatment and is considered as an assisted reproductive technology (ART). INVOcell is an intravaginal culture (IVC) system used for preparing, holding and transferring human gametes or embryos during vaginal in vitro fertilization or intravaginal culture procedures (IVF/IVC). The INVOcell system consists of various components: INVOcell Culture Device, INVOcell Retention Device and INVOcell Holding Block. The INVO Procedure is a fertility treatment option allowing fertilization and early embryo development to take place inside the woman’s body. The INVO Procedure is an IVC or in vivo incubation assisted reproduction technique available.

INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) Recent Trading Information

INVO BIOSCIENCE, INC. (OTCMKTS:IVOB) closed its last trading session 00.000 at 0.370 with 64,550 shares trading hands.

An ad to help with our costs